1. Home
  2. PTGX

as 10-30-2025 9:33am EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Founded: 2006 Country:
United States
United States
Employees: N/A City: NEWARK
Market Cap: 4.0B IPO Year: 2016
Target Price: $78.11 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.80 EPS Growth: -70.73
52 Week Low/High: $33.31 - $93.25 Next Earning Date: 10-31-2025
Revenue: $209,180,000 Revenue Growth: -34.45%
Revenue Growth (this year): -85.29% Revenue Growth (next year): 142.86%

Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Waddill William D. PTGX Director Oct 10 '25 Sell $78.53 12,000 $979,480.00 13,130
Waddill William D. PTGX Director Sep 22 '25 Sell $64.25 4,000 $257,000.00 13,130

Share on Social Networks: